BioPharmSignal logoBioPharmSignal

Biotech News

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

Cogent Biosciences (COGT)Cogent BiosciencesConference / presentation

WALTHAM, Mass. and BOULDER, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the Jefferies Global Healthcare Conference in New

Open original release

Related news

IDYAIDEAYA Biosciences2026-05-26 10:00 EST

IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

ERASErasca2026-05-27 12:00 EST

Erasca to Present at the Jefferies Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

COGTCogent Biosciences2026-05-12 13:30 EST

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

KURAKura Oncology2026-05-06 11:30 EST

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

COGTCogent Biosciences2026-05-28 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

View all latest news

Cogent Biosciences

Cogent Biosciences is a precision-oncology company focused on genetically defined cancer targets. Its pipeline is built to address specific kinase-driven cancers with targeted therapy.

Recent company news

COGTCogent Biosciences2026-05-30 12:00 EST

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

COGTCogent Biosciences2026-05-28 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

COGTCogent Biosciences2026-05-27 12:00 EST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

COGTCogent Biosciences2026-05-12 13:30 EST

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

COGTCogent Biosciences2026-05-05 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

Stock data

Close
40.44 USD
Market cap
5.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States